Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and/or Bevacizumab with Chemotherapy in Untreated Metastatic Colorectal Cancer
NCT00265850Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2005
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of KL-140 and bevacizumab in colorectal cancer (CRC) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 5 years. Started Nov 2005; status: completed.
02
Drugs
KL-140bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00265850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265850.